Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical–Radiological Outcomes and Safety Profile

CardioVascular and Interventional Radiology

Volumn 38, Issue 1, 2015, Pages 129-134

  Spreafico, Carlo ^a   Cascella, Tommaso ^a   Facciorusso, Antonio ^a   Sposito, Carlo ^a   Rodolfo, Lanocita ^a   Morosi, Carlo ^a   Civelli, Enrico M ^a   Vaiani, Marta ^a   Bhoori, Sherrie ^a   Pellegrinelli, Alessandro ^a   Marchianò, Alfonso ^a   Mazzaferro, Vincenzo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROTRIANISENE; DOXORUBICIN; IODINATED POPPYSEED OIL; KETOROLAC; ONDANSETRON; PARACETAMOL; ANTINEOPLASTIC ANTIBIOTIC; CONTRAST MEDIUM; IOPAMIDOL; MICROSPHERE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL EXAMINATION; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; ENERGY; ESOPHAGUS VARICES; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MEDICAL ONCOLOGIST; OUTCOME ASSESSMENT; PATIENT SAFETY; PORTAL HYPERTENSION; PRIORITY JOURNAL; SUPERIOR MESENTERIC ARTERY; ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC USE; FEMALE; IMAGE QUALITY; LIVER TUMOR; MALE; MIDDLE AGED; PILOT STUDY; PROCEDURES; PROSPECTIVE STUDY; RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; DOXORUBICIN; FEMALE; HUMANS; IOPAMIDOL; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE ENHANCEMENT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930928856     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-014-0907-0     Document Type: Article

References (22)

1. Llovet JM, Bruix J (2003) Systemic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442
2. Poon RT, Tso WK, Pang RW et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108
3. Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481
4. Lencioni R, de Baere T, Burrel M et al (2012) Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC beads (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 35:980–985
5. Lencioni R, Crocetti L (2010) Loco-regional treatment of hepatocellular carcinoma. Radiology 262:43–58
6. Malagari K, Alexopoulou E, Chatzimichail K et al (2008) Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC beads. Abdom Imaging 33:512–519
7. Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52
8. Nicolini A, Martinetti L, Crespi S et al (2010) Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21:327–332
9. Bonomo G, Pedicini V, Monfardini L et al (2010) Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol 33:552–559
10. Geschwind J (2012) Doxorubicin eluting bead sizes 100–300 μm and 70–150 μm in the VX2 model. Paper presented at: ECIO 2012 (Terumo Symposium)
11. EASL-EORTC (2012) Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943
12. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338
13. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655
14. National Cancer Institute (2009) Common terminology criteria for adverse events v4.0. NCI, NIH, DHHS. May 29, 2009. NIH publication 09-7473
15. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60
16. Bruix J, Sherman M (2011) Practice guidelines committee, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma. An update. Hepatology 53:1020–1022
17. Burrel M, Reig M, Forner A et al (2012) Survival of patients with hepatocellular carcinoma treated by transarterial embolization (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 56:1330–1335
18. Malagari K, Pomoni M, Moschouris H et al (2012) Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 35:1119–1128
19. Jun Song M, Chun HL, Song DS et al (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57:1244–1250
20. Nicolini D, Svegliati-Baroni G, Candelari R et al (2013) Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 19:5622–5632
21. Sacco R, Bargellini I, Bertini M et al (2011) Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22:1545–1552
22. Malagari K, Pomoni M, Moschouris H et al (2014) Chemoembolization of hepatocellular carcinoma with Hepasphere 30–60 µm. Safety and efficacy study. Cardiovasc Intervent Radiol 37:165–175